NEJM Evidence publishes positive results from pivotal bladder cancer clinical trial

Teclistamab improves outcomes in relapsed MM, phase III trial finds

An international phase III study showed that patients with relapsed multiple myeloma treated with teclistamab lived longer and remained in remission significantly longer than patients receiving standard therapies.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer, according to the results of a multicenter clinical trial led by researchers at the Johns Hopkins University School of Medicine, Johns Hopkins Kimmel Cancer Center, Department of Radiation Oncology and Molecular Radiation Sciences, and Brady Urological Institute.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.

June 05, 2026

Vol.52 No.22

Clinical Roundup

OST-HER2 achieves 2.5-year OS in fully resected pulmonary metastatic osteosarcoma, phase IIb trial finds

OST-HER2 (OST31-164) achieved statistically significant benefit for treated patients in overall survival at the 2.5-year timepoint in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (75% vs. 47%, p = 0.003).

June 05, 2026

Vol.52 No.22

Clinical Roundup

Catheter with specialized nanosensors could enable earlier detection of bladder cancer, MIT study finds

While treatment is often successful, bladder cancer has one of the highest rates of recurrence of any cancer: Following treatment, about 50% of patients develop tumors again within the next five years. This makes it one of the most expensive cancers for society to treat.

June 05, 2026

Vol.52 No.22

Drugs & Targets

FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer

FDA approved Imfinzi (durvalumab) in combination with Bacillus Calmette-Guerin for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer.

June 05, 2026

Vol.52 No.22

NEJM Evidence publishes positive results from pivotal bladder cancer clinical trial

YOU MAY BE INTERESTED IN

Teclistamab improves outcomes in relapsed MM, phase III trial finds

Adding immunotherapy to radiation improves disease-free survival in localized prostate cancer, phase III trial finds

Camizestrant combination delayed time to first progression by 55% in patients with advanced HR+ breast cancer with ESR1 tumor mutation

OST-HER2 achieves 2.5-year OS in fully resected pulmonary metastatic osteosarcoma, phase IIb trial finds

Catheter with specialized nanosensors could enable earlier detection of bladder cancer, MIT study finds

FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer

Renew today!

Subscriber content

Never miss an issue!

Login